In addition, HBM1047 had a favorable PK profile in mice and exhibited good developability properties. Conclusions In conclusion, HBM1047 represents a novel fully human anti-CD200R1 antagonistic antibody with promising therapeutic potential for the treatment of cancer.
2 years ago
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD200 (CD200 Molecule)